Agenus rises on FDA's 'fast-track' tag for cancer therapy

Agenus

17/04/2023 16:03

(Updates)
    ** Shares of cancer therapy developer Agenus Inc  AGEN.O  rise 11.38% to $1.61 in morning
trade
    ** Company says U.S. FDA has granted "fast-track" designation for its experimental
combination therapy to treat a type of colorectal cancer
    ** AGEN is testing drug candidate botensilimab in combination with balstilimab in a
mid-stage study in non-microsatellite instability-high colorectal cancer patients
    ** FDA's fast-track tag is aimed at accelerating the development and review of products,
which are intended to treat serious diseases
    ** Including session's moves, stock down ~34% this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))